Literature DB >> 26974271

A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation.

G S Hobbs1,2,3, N Kaur1, P Hilden4, D Ponce1,2, C Cho1,2, H R Castro-Malaspina1,2, S Giralt1,2, J D Goldberg1,2, A A Jakubowski1,2, E B Papadopoulos1,2, C Sauter1,2, G Koehne1,2, J Yahalom2,5, S Delvin2,4, J N Barker1,2, M-A Perales1,2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26974271      PMCID： PMC5330665          DOI： 10.1038/bmt.2016.36

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  16 in total

1.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

2.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation.

Authors:  R Storb; C Yu; J L Wagner; H J Deeg; R A Nash; H P Kiem; W Leisenring; H Shulman
Journal:  Blood       Date:  1997-04-15       Impact factor: 22.113

3.  Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients.

Authors:  A Bryant; I Nivison-Smith; E S Pillai; G Kennedy; A Kalff; D Ritchie; B George; M Hertzberg; S Patil; A Spencer; K Fay; P Cannell; L Berkahn; R Doocey; R Spearing; J Moore
Journal:  Bone Marrow Transplant       Date:  2013-09-23       Impact factor: 5.483

4.  A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation.

Authors:  Doris M Ponce; Craig Sauter; Sean Devlin; Marissa Lubin; Anne Marie Gonzales; Nancy A Kernan; Andromachi Scaradavou; Sergio Giralt; Jenna D Goldberg; Guenther Koehne; Miguel A Perales; James W Young; Hugo Castro-Malaspina; Ann Jakubowski; Esperanza B Papadopoulos; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-14       Impact factor: 5.742

5.  Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure.

Authors:  César O Freytes; Mei-Jie Zhang; Jeanette Carreras; Linda J Burns; Robert Peter Gale; Luis Isola; Miguel-Angel Perales; Matthew Seftel; Julie M Vose; Alan M Miller; John Gibson; Thomas G Gross; Philip A Rowlings; David J Inwards; Santiago Pavlovsky; Rodrigo Martino; David I Marks; Gregory A Hale; Sonali M Smith; Harry C Schouten; Simon Slavin; Thomas R Klumpp; Hillard M Lazarus; Koen van Besien; Parameswaran N Hari
Journal:  Biol Blood Marrow Transplant       Date:  2011-12-23       Impact factor: 5.742

6.  Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.

Authors:  Jens Marcus Chemnitz; Marie von Lilienfeld-Toal; Udo Holtick; Sebastian Theurich; Alexander Shimabukuro-Vornhagen; Anke Krause; Peter Brossart; Michael Hallek; Christof Scheid
Journal:  Ann Hematol       Date:  2011-05-17       Impact factor: 3.673

7.  Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

Authors:  Ulrike Bacher; Evgeny Klyuchnikov; Jennifer Le-Rademacher; Jeanette Carreras; Philippe Armand; Michael R Bishop; Christopher N Bredeson; Mitchell S Cairo; Timothy S Fenske; Cesar O Freytes; Robert Peter Gale; John Gibson; Luis M Isola; David J Inwards; Ginna G Laport; Hillard M Lazarus; Richard T Maziarz; Peter H Wiernik; Harry C Schouten; Shimon Slavin; Sonali M Smith; Julie M Vose; Edmund K Waller; Parameswaran N Hari
Journal:  Blood       Date:  2012-09-24       Impact factor: 22.113

8.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.

Authors:  Sergio Giralt; Karen Ballen; Douglas Rizzo; Andreas Bacigalupo; Mary Horowitz; Marcelo Pasquini; Brenda Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

Review 9.  Diagnosis and manifestations of chronic graft-versus-host disease.

Authors:  Alexandra H Filipovich
Journal:  Best Pract Res Clin Haematol       Date:  2008-06       Impact factor: 3.020

10.  High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia.

Authors:  Doris M Ponce; Patrick Hilden; Sean M Devlin; Molly Maloy; Marissa Lubin; Hugo Castro-Malaspina; Parastoo Dahi; Katharine Hsu; Ann A Jakubowski; Nancy A Kernan; Guenther Koehne; Richard J O'Reilly; Esperanza B Papadopoulos; Miguel-Angel Perales; Craig Sauter; Andromachi Scaradavou; Roni Tamari; Marcel R M van den Brink; James W Young; Sergio Giralt; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-31       Impact factor: 5.742
View more
  5 in total

1.  Cytomegalovirus Infection in Allogeneic Hematopoietic Cell Transplantation Managed by the Preemptive Approach: Estimating the Impact on Healthcare Resource Utilization and Outcomes.

Authors:  Yao-Ting Huang; Yiqi Su; Seong Jin Kim; Paige Nichols; Daniel Burack; Molly Maloy; Sergio Giralt; Miguel-Angel Perales; Ann A Jakubowski; Genovefa A Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-24       Impact factor: 5.742

2.  Impact of Preemptive Therapy for Cytomegalovirus on Hospitalizations and Cost after Hematopoietic Stem Cell Transplantation.

Authors:  Jiaqi Fang; Yiqi Su; Phaedon D Zavras; Amit D Raval; Yuexin Tang; Miguel-Angel Perales; Sergio Giralt; Anat Stern; Genovefa A Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2020-07-05       Impact factor: 5.742

3.  Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice: A Retrospective Single-Center Cohort Study.

Authors:  Phaedon Zavras; Yiqi Su; Jiaqi Fang; Anat Stern; Nitasha Gupta; Yuexin Tang; Amit Raval; Sergio Giralt; Miguel Angel Perales; Ann A Jakubowski; Genovefa A Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2020-04-19       Impact factor: 5.742

4.  A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.

Authors:  Anat Stern; Yiqi Su; Yeon Joo Lee; Susan Seo; Brian Shaffer; Roni Tamari; Boglarka Gyurkocza; Juliet Barker; Yael Bogler; Sergio Giralt; Miguel-Angel Perales; Genovefa A Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2020-02-20       Impact factor: 5.742

5.  Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.

Authors:  Yael Bogler; Anat Stern; Yiqi Su; Yeon Joo Lee; Susan K Seo; Brian Shaffer; Miguel-Angel Perales; Genovefa A Papanicolaou; Dionysios Neofytos
Journal:  Med Mycol       Date:  2021-10-04       Impact factor: 3.747
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.